World's Best Scientists 2026 revealed!
Bengt Glimelius

Bengt Glimelius

Award Badge
Medicine
Sweden
2023

D-Index & Metrics

Medicine

D-Index
144
Citations
103195
World Ranking
1413
National Ranking
30

Bengt Glimelius publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Bengt Glimelius sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,049 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Bengt Glimelius D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Bengt Glimelius sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 144 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Sweden Leader Award

Overview

Bengt Glimelius is a researcher affiliated with Uppsala University in Sweden, specializing in medicine with a focus on oncology and colorectal cancer. Their work encompasses various aspects of colorectal cancer treatments, surgical interventions, screening, and genetic factors, alongside broader interests in cancer genomics and diagnostics as well as gastric cancer management.

Their research portfolio includes numerous publications in prominent venues with a significant number appearing in the following journals:

  • Annals of Oncology
  • Cancers
  • Journal of Clinical Oncology
  • Radiotherapy and Oncology
  • UNC Libraries

Glimelius' recent influential papers demonstrate a concentration on rectal and colon cancer treatment methods. Selected recent publications include:

  • "Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial" (2020) published in The Lancet Oncology
  • "Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial" (2023) in Journal of Clinical Oncology
  • "Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery" (2023) in Annals of Surgery
  • "Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial" (2020) in Radiotherapy and Oncology
  • "Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study" (2023) in Cancer Cell

The scientist frequently collaborates with several co-authors who have contributed alongside in numerous publications. These include:

  • Tobias Sjöblom
  • Per J. Nilsson
  • Per Pfeiffer
  • Pia Österlund
  • Corrie A.M. Marijnen

In terms of academic fields, the main area of study is medicine, with a more refined focus on:

  • Oncology
  • Surgery
  • Pathology and Forensic Medicine
  • Pulmonary and Respiratory Medicine
  • Cancer Research

The dominant topics covered in Bengt Glimelius's research include colorectal cancer treatments and studies, colorectal cancer surgical treatments, colorectal and anal carcinomas, colorectal cancer screening and detection, genetic factors in colorectal cancer, gastric cancer management and outcomes, and cancer genomics and diagnostics.

Best Publications

  • Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer

    Ellen Kapiteijn;Corrie A.M. Marijnen;Iris D. Nagtegaal;Hein Putter

  • A pathology atlas of the human cancer transcriptome

    Mathias Uhlen;Mathias Uhlen;Cheng Zhang;Sunjae Lee;Evelina Sjöstedt;Evelina Sjöstedt

  • Improved survival with preoperative radiotherapy in resectable rectal cancer.

    B Cedermark;M Dahlberg;B Glimelius

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli

  • Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial

    Willem van Gijn;Carrie A. M. Marijnen;Iris D. Nagtegaal;Elma Meershoek-Klein Kranenbarg

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Bengt Glimelius;Lars Påhlman;A. Cervantes

  • Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

  • The TME Trial After a Median Follow-Up of 6 Years: Increased Local Control but No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma

    Koen C. M. J. Peeters;Corrie A. M. Marijnen;Iris D. Nagtegaal;Elma Klein Kranenbarg

  • Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer

    B Glimelius;K Ekström;K Hoffman;W Graf

  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial

    Pascal Hammel;Florence Huguet;Jean-Luc van Laethem;David Goldstein

  • Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.

    Renu R Bahadoer;Esmée A Dijkstra;Boudewijn van Etten;Corrie A M Marijnen;Corrie A M Marijnen

  • Swedish rectal cancer trial : Long lasting benefits from radiotherapy on survival and local recurrence rate

    Joakim Folkesson;Helgi Birgisson;Lars Pahlman;Bjorn Cedermark

  • Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

    B Glimelius;Katarina Hoffman;P-O Sjoden;G Jacobsson

  • Sexually Transmitted Infection as a Cause of Anal Cancer

    Frisch M;Glimelius B;van den Brule Aj;Wohlfahrt J

  • Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

    Lars Påhlman;Bengt Glimelius

  • Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    Richard Herrmann;György Bodoky;Thomas Ruhstaller;Bengt Glimelius

  • DUTCH COLORECTAL CANCER GROUP. PREOPERATIVE RADIOTHERAPY COMBINED WITH TOTAL MESORECTAL EXCISION FOR RESECTABLE RECTAL CANCER

    E Kapiteijn;C A Marijnen;I D Nagtegaal;H Putter

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

Frequent Co-Authors

Lars Påhlman
Lars Påhlman Uppsala University
Hans-Olov Adami
Hans-Olov Adami Karolinska Institute
Mads Melbye
Mads Melbye University of Copenhagen
Peter Nygren
Peter Nygren Uppsala University
Karin E. Smedby
Karin E. Smedby Karolinska University Hospital
Henrik Hjalgrim
Henrik Hjalgrim Statens Serum Institut
Christer Sundström
Christer Sundström Uppsala University
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Ellen T. Chang
Ellen T. Chang Stanford University
Angela Brooks-Wilson
Angela Brooks-Wilson Simon Fraser University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean medical school. There are several respected online degrees that open doors within the healthcare field. These programs are ideal for those who want to play a critical role in healthcare while balancing studies with work or family commitments.

If you’re interested in leadership roles, consider a healthcare administration degree online. This program teaches management, policy, and organizational skills. For advanced positions, you might research the most affordable online mha programs, which offer specialized expertise at the graduate level.

Nursing professionals wanting to impact patient care can look into cheap dnp online programs. A Doctor of Nursing Practice prepares you for leadership or clinical roles with a flexible online format. Pharmacists can boost their qualifications through an online pharmd degree, tailored for career advancement or specialized practice.

These pathways provide affordable and flexible alternatives to traditional on-campus degrees, supporting a variety of rewarding healthcare careers beyond medicine itself.

Best Scientists Citing Bengt Glimelius

Trending Scientists

Recently Published Articles